Truist Financial analyst Jailendra Singh maintains $Evolent Health (EVH.US)$ with a buy rating, and adjusts the target price from $33 to $24.
According to TipRanks data, the analyst has a success rate of 30.3% and a total average return of -16.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Evolent Health (EVH.US)$'s main analysts recently are as follows:
The reduction in the third-quarter performance of Evolent Health is noted as disheartening but not an isolated case given the prevailing risk climate. The essential business structure is still considered to be solid.
Evolent Health's Q3 EBITDA was significantly lower than consensus, influenced by a substantial rise in Oncology costs, witnessed both retrospectively and within the quarter. On a positive note, the company secured $200M in new run-rate business during Q3, underscoring the growing demand for specialty care management.
Evolent Health's third-quarter results were considered disappointing, with previous expectations indicating the company was positioned to recover a significant portion of higher costs via contractual rate increases. Despite this, prevailing sentiment among investors appears skeptical regarding the company's ability to achieve approximately $300M of EBITDA. Nonetheless, the prevailing opinion among analysts is that the recent developments are atypical, and there is confidence that Evolent's margins will stabilize as planned price adjustments are implemented.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
儲億銀行分析師Jailendra Singh維持$Evolent Health (EVH.US)$買入評級，並將目標價從33美元下調至24美元。
根據TipRanks數據顯示，該分析師近一年總勝率為30.3%，總平均回報率為-16.7%。
此外，綜合報道，$Evolent Health (EVH.US)$近期主要分析師觀點如下：
Evolent Health第三季度業績的下降令人沮喪，但鑑於當前的風險環境，這並非個別情況。基本業務結構仍然被認爲是穩固的。
受腫瘤學成本大幅上漲的影響，Evolent Health第三季度的息稅折舊攤銷前利潤明顯低於市場預期，無論是回顧性還是本季度內。積極的一面是，該公司在第三季度獲得了2億美元的新運營利率業務，這凸顯了對專業護理管理的需求不斷增長。
Evolent Health的第三季度業績被認爲令人失望，此前的預期表明，該公司有望通過提高合同利率來收回很大一部分較高的成本。儘管如此，投資者普遍對該公司實現約3億美元息稅折舊攤銷前利潤的能力持懷疑態度。儘管如此，分析師普遍認爲，近期的事態發展並不典型，並且有信心隨着計劃的價格調整的實施，Evolent的利潤率將穩定下來。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
